AzTrials
AzTrials

Parkinson DiseasePhase 2NCT02687542

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A Phase 2 study testing PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD) in people with Parkinson Disease, run by Pfizer at 57 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations. Read more about this study

Who is it for?
Ages 40 to 85 years
Conditions the study is for
Parkinson Disease
What is being tested?
PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
108 participants
Where
57 sitesin 6 countries
Study dates
3 Mar 2016to 10 Nov 2017
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Females of non-childbearing potential and/or male subjects between the ages of 40 and 85 years, inclusive.
  • Clinical diagnosis of Parkinson's disease.
  • Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Who cannot join

  • Female of childbearing potential
  • History or presence of atypical Parkinsonian syndrome.
  • History of surgical intervention for Parkinson's disease.
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality.
  • Any condition possibly affecting drug absorption.
  • Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

Trial locations and contacts

57 sites in 6 countries.

57 sites in 6 countries

United States33 sites
  • Dent Neurologic Institute

    Amherst, New York, 14226

  • Dent Neurosciences Research Center ,Inc. DBA Dent Neurologic Institute

    Amherst, New York, 14226

  • Arcadia Neurology Center

    Arcadia, California, 91006

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115

  • Rush University Medical Center

    Chicago, Illinois, 60612

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Duke University Medical center

    Durham, North Carolina, 27705

  • Duke University/Duke Neurology/Department of Neurology

    Durham, North Carolina, 27705

  • Associated Neurologists of Southern Connecticut, PC

    Fairfield, Connecticut, 06824

  • University of Florida Center for Movement Disorders and Neurorestoration

    Gainesville, Florida, 32607

  • AS Clinical Research Consultants of North Texas, PLLC

    Greenville, Texas, 75401

  • Baylor College of Medicine

    Houston, Texas, 77030

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana, 46202

  • Booth Gardner Parkinson's Care Center

    Kirkland, Washington, 98034

  • Faculty Physicians and Surgeons of Loma Linda University School of Medicine

    Loma Linda, California, 92354

  • CRI Worldwide, LLC

    Marlton, New Jersey, 08053

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92658

  • Hoag Memorial Hospital

    Newport Beach, California, 92663

  • Dent Neurologic Institute

    Orchard Park, New York, 14127

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida, 32174

  • SC3 Research Group, Inc

    Pasadena, California, 91105

  • Xenoscience, Inc

    Phoenix, Arizona, 85004

  • St Joseph's Hospital and Medical Center

    Phoenix, Arizona, 85013

  • Rhode Island Hospital/ Brown University Medical School

    Providence, Rhode Island, 02903

  • Wake Research Associates, LLC

    Raleigh, North Carolina, 27612

  • University of South Florida

    Tampa, Florida, 33613

  • University of Toledo

    Toledo, Ohio, 43614

  • Neurosearch-Torrance

    Torrance, California, 90505

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma, 74136

  • Vero Beach Neurology and Research Institute

    Vero Beach, Florida, 32960

  • Abington Neurological Associates, Ltd.

    Willow Grove, Pennsylvania, 19090

Other trials in United States

France6 sites
  • CHU de Grenoble Alpes

    Grenoble, 38043 Cedex 9

  • CHU de Grenoble Alpes

    La Tronche, 38700

  • CHRU de Lille-Hopital Roger Salengro

    Lille, 59037 cedex

  • Hopital de la Timone APHM

    Marseille, 13385 cedex 05

  • Hopital de La Timone

    Marseille, 13385 cedex 05

  • Hopital La Pitie-Salpetriere

    Paris, 75013

Other trials in France

Spain6 sites
  • Hospital Clinic i Provincial de Barcelona

    Barcelona, 08036

  • Policlinica de Guipuzcoa

    Donostia / San Sebastian, Guipuzcoa, 20009

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907

  • Hospital Universitario de la Princesa

    Madrid, 28006

  • Hospital Clinico Universitario

    Santiago de Compostela, A Coruna, 15706

  • Hospital Universitario y Politecnico la Fe

    Valencia, 46026

Other trials in Spain

Germany5 sites
  • St. Josef-Hospital GmbH

    Bochum, 44791

  • Universitaetsklinikum Carl Gustav Carus Klinik und Poliklinik fur Neurologie

    Dresden, 01307

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, 79106

  • Klinikum rechts der Isar der Technischen Universitaet Muenchen

    München, 81675

  • Universitaetsklinik Ulm

    Ulm, 89081

Other trials in Germany

Japan5 sites
  • Asahikawa Medical center

    Asahikawa, Hokkaido, 0708644

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-8431

  • Tazuke Kofukai Medical Research Institute Kitano Hospital

    Kita-ku, Osaka, 530-8480

  • Medical Corporation Abe Neurology Clinic

    Morioka, Iwate, 020-0878

  • Osaka University Hospital

    Suita, Osaka, 565-0871

Other trials in Japan

Canada2 sites
  • Montreal Neurological Hospital Research Pharmacy

    Montreal, Quebec, H3A 2B4

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, H3A 2B4

Other trials in Canada

About this study

Official title: A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Read the detailed description

The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.

Being tested
Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
Keywords
Parkinson Disease, Motor Fluctuation
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Placebo

  • PF-06649751 low dose (1 mg QD)Drug

    PF-06649751 low dose (1 mg QD)

  • PF-06649751 middle dose 1 (3 mg QD)Drug

    PF-06649751 lower middle dose 1 (3 mg QD)

  • PF-06649751 middle dose 2 (7 mg QD)Drug

    PF-06649751higher middle dose 2 (7 mg QD)

  • PF-06649751 high dose (15 mg QD)Drug

    PF-06649751 high dose (15 mg QD)

Study groups in NCT02687542
Study groupRoleWhat they receive
PlaceboPlacebo comparatorPlacebo
Receives: Drug: Placebo
PF-06649751 low dose (1 mg QD)ExperimentalPF-06649751 low dose level (1 mg QD)
Receives: Drug: PF-06649751 low dose (1 mg QD)
PF-06649751 middle dose 1 (3 mg QD)ExperimentalPF-06649751 lower middle dose 1 (3 mg QD)
Receives: Drug: PF-06649751 middle dose 1 (3 mg QD)
PF-06649751 middle dose 2 (7 mg QD)ExperimentalPF-06649751 higher middle dose 2 (7 mg QD)
Receives: Drug: PF-06649751 middle dose 2 (7 mg QD)
PF-06649751 high dose (15 mg QD)ExperimentalPF-06649751 high dose (15 mg QD)
Receives: Drug: PF-06649751 high dose (15 mg QD)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Daily OFF Time at Week 10

    A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization).

    The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.

    Measured: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).

Secondary outcomes (12)
  1. Change From Baseline in Daily OFF Time

    A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization).

    The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.

    Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).

  2. Change From Baseline in Daily ON Time With Troublesome Dyskinesia

    A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep.

    The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit.

    Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).

  3. Change From Baseline in Daily ON Time Without Troublesome Dyskinesia

    A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep.

    The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit.

    Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Measured: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)

  4. Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

    MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease.

    Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Measured: Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement

  5. Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score

    Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10

    Measured: Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement

  6. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed.

    Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards.

    Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.

    Measured: Baseline (Day 0) to Week 17

  7. Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization

    Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.

    Measured: Baseline (Day 0) to Week 17

  8. Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization

    The average of the triplicate readings of ECG data was collected at each assessment time.

    Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.

    Measured: Baseline (Day 0) to Week 17

  9. Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits

    The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation:

    • Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior.
    • Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category.
    • Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.

    Measured: Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119

  10. Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)

    The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease.

    The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding [performing tasks and repeating activities] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores * (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD.

    The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.

    Measured: Baseline (Day 0) and Weeks 5, 10 and 15

  11. Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119

    The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up.

    The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items * (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.

    Measured: Days 105 and 119

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage.

    An SAE was any untoward medical occurrence at any dose that:

    • Resulted in death;
    • Was life threatening (immediate risk of death);
    • Required inpatient hospitalization or prolongation of existing hospitalization;
    • Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions);
    • Resulted in congenital anomaly/birth defect.

    Measured: Day 1 to follow-up (Week 19 visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2016 (estimated)
  2. Study start3 Mar 2016
  3. Primary completion10 Nov 2017
  4. Study completion10 Nov 2017

Why it stopped: Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
108 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02687542
Sponsor's protocol ID
B7601003
Other IDs
2015-004912-39, A-ROSE PD, A-ROSE, 2015
Status last verified
Oct 2020
First submitted
29 Jan 2016
Last updated
23 Nov 2020
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD) and PF-06649751 middle dose 2 (7 mg QD) in people with Parkinson Disease, run by Pfizer at 57 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 23 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 57 sites in United States, France, Spain, Germany, Japan and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Dec 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Daily OFF Time at Week 10 (time frame: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in